Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 1
2019 1
2020 2
2021 4
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. Francque SM, et al. N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205. N Engl J Med. 2021. PMID: 34670042 Clinical Trial.
Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
Møllerhøj MB, Veidal SS, Thrane KT, Oró D, Overgaard A, Salinas CG, Madsen MR, Pfisterer L, Vyberg M, Simon E, Broermann A, Vrang N, Jelsing J, Feigh M, Hansen HH. Møllerhøj MB, et al. Clin Transl Sci. 2022 May;15(5):1167-1186. doi: 10.1111/cts.13235. Epub 2022 Feb 24. Clin Transl Sci. 2022. PMID: 35143711 Free PMC article.
Lanifibranor and NASH resolution.
Kotsiliti E. Kotsiliti E. Nat Rev Gastroenterol Hepatol. 2021 Dec;18(12):832. doi: 10.1038/s41575-021-00544-z. Nat Rev Gastroenterol Hepatol. 2021. PMID: 34725496 No abstract available.
Modelling fatty liver disease with mouse liver-derived multicellular spheroids.
van Os EA, Cools L, Eysackers N, Szafranska K, Smout A, Verhulst S, Reynaert H, McCourt P, Mannaerts I, van Grunsven LA. van Os EA, et al. Biomaterials. 2022 Nov;290:121817. doi: 10.1016/j.biomaterials.2022.121817. Epub 2022 Sep 28. Biomaterials. 2022. PMID: 36208587 Free article.
Magnetic-Assisted Treatment of Liver Fibrosis.
Levada K, Omelyanchik A, Rodionova V, Weiskirchen R, Bartneck M. Levada K, et al. Cells. 2019 Oct 19;8(10):1279. doi: 10.3390/cells8101279. Cells. 2019. PMID: 31635053 Free PMC article. Review.
A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study.
Sven M F, Pierre B, Manal F A, Quentin M A, Elisabetta B, Vlad R, Philippe HM, Bruno S, Jean-Louis J, Pierre B, Jean-Louis A. Sven M F, et al. Contemp Clin Trials. 2020 Nov;98:106170. doi: 10.1016/j.cct.2020.106170. Epub 2020 Oct 8. Contemp Clin Trials. 2020. PMID: 33038502 Free article. Clinical Trial.
14 results